avx recent selling , page-5

Re Supertramp's remark:

"Stockmarket valuations are crazy. How can pxs be worth $427m and avx $63m."

In fairness, PXS is a lot further down the track than AVX in terms of getting a drug to market. PXS has approved products and other potential blockbusters at marketing application stage or phase 3. It also looks like PXS will have the first drug in a big market (bronchiectasis), whereas AVX has a very good version of a me-too drug where there are more than 20 other drugs already competing (there is still a clear niche for ATC though). Avexa has a very promising drug I think it will get there in the end and the share price will be much higher, but it is still a risk and still needs to get money from somewhere to get its treatment to market. That's why it's in the doldrums - money is hard to come by. Agreed though - it's an obvious takeover target for big pharma. I hold both AVX and PXS.